[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-362010-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-362010-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","viral-warfare-unleashing-engineered-oncolytic-viruses-to-outsmart-cancers-defenses-review","Viral warfare - unleashing engineered oncolytic viruses to outsmart cancer’s defenses - Review","","Oncolytic virotherapy (OVT) is presented as an innovative cancer strategy using engineered viruses that selectively infect, replicate in, and destroy malignant cells while sparing healthy tissue. The review explains how oncolytic viruses also exploit tumor-specific metabolic, antiviral, and immunological vulnerabilities to remodel the tumor microenvironment and trigger systemic antitumor immunity. It surveys persistent limitations such as delivery inefficiency, immune clearance, and tumor heterogeneity, then details recent engineering advances and rational combination approaches.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/viral-warfare-unleashing-engineered-oncolytic-viruses-to-outsmart-cancers-defenses-review/362010/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/viral-warfare-unleashing-engineered-oncolytic-viruses-to-outsmart-cancers-defenses-review/362010.png","ImageObject",300,407,{"name":42,"@type":43},"Liam","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-29","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",12,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"How do engineered oncolytic viruses treat cancer beyond direct tumor cell killing?","Question",{"text":63,"@type":64},"They can remodel the tumor microenvironment by exploiting tumor-specific vulnerabilities and trigger systemic antitumor immunity, including immunogenic cell death and T-cell infiltration and activation.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What main barriers limit the clinical success of oncolytic virotherapy as a standalone treatment?",{"text":68,"@type":64},"Key barriers include inefficient intratumoral virus delivery, immune clearance, and tumor heterogeneity, which reduce therapeutic effectiveness.",{"name":70,"@type":61,"acceptedAnswer":71},"What types of progress are discussed for improving oncolytic virus performance?",{"text":72,"@type":64},"The review highlights advances in OV engineering that enhance viral tropism, immune evasion, and transgene delivery, supporting better targeting, penetration, and sustained immune activation.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},362010,1790171536,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":140,"language":141,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":12,"update_tm":145,"read_time":146,"preview_page_count":33,"preview_urls":147},8796095461564,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","TYPE Review  \nPUBLISHED 25 August 2025  \nDOI 10.3389/fimmu.2025.1618751  \nOPEN ACCESS  \nEDITED BY  \nTilman Sanchez-Elsner,  \nUniversity of Southampton, United Kingdom  \nREVIEWED BY  \nJia Yao,  \nEmory University, United States Yanhua Gao,  \nUniversity of Pittsburgh, United States  \n*CORRESPONDENCE  \nJean Christopher Chamcheu  \n[jeanchristopher.c@subr.edu](jeanchristopher.c@subr.edu);  \n[jchamcheu@lsu.edu](jchamcheu@lsu.edu)  \nRECEIVED 26 April 2025  \nACCEPTED 30 July 2025  \nPUBLISHED 25 August 2025  \nCITATION  \nOmolekan TO, Folahan JT, Tesfay MZ, Mohan H, Dutta O, Rahimian L, Ferdous KU, Ghavimi R, Cios A, Beng TK, Francis J, D'Auvergne O, Borad MJ, Kousoulas KG, DiGiuseppe S, Nagalo BMand Chamcheu JC (2025) Viral warfare:  \nunleashing engineered oncolytic viruses to outsmart cancer ’s defenses.  \nFront. Immunol. 16:1618751 .  \ndoi: 10.3389/fimmu.2025.1618751  \nCOPYRIGHT  \n© 2025 Omolekan, Folahan, Tesfay, Mohan, Dutta, Rahimian, Ferdous, Ghavimi, Cios, Beng, Francis, D'Auvergne, Borad, Kousoulas, DiGiuseppe, Nagalo and Chamcheu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nViral warfare: unleashing engineered oncolytic viruses to outsmart cancer’s defenses  \nTolulope O. Omolekan 1, Joy T. Folahan 1, Mulu Z. Tesfay 2,3, Harikrishnan Mohan 1, Ojasvi Dutta 1, Leila Rahimian 1, Khandoker Usran Ferdous 2,3, Reza Ghavimi 1,  \nAleksandra Cios 4,5, Timothy K. Beng 6, Joseph Francis 7, Oswald D'Auvergne 8, Mitesh J. Borad 9, Konstantin G. Kousoulas 1, Stephen DiGiuseppe 10, Bolni Marius Nagalo 4,5  \nand Jean Christopher Chamcheu 1,8*  \n1 Department of Pathological Sciences, School of Veterinary Medicine, Louisiana State University, Baton Rouge, LA, United States, 2 Department of Pathology, University of Arkansas for Medical Sciences (UAMS), Little Rock, AR, United States, 3The Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, Little Rock, AR, United States, 4 Department of Pharmacology and Physiology, University of Maryland School of Medicine, Baltimore, MD, United States, 5 Marlene and Stewart Greenebaum NCI Comprehensive Cancer Center, University of Maryland School of Medicine, Baltimore, MD, United States, 6 Department of Chemistry, Central Washington University, Ellensburg, WA, United States, 7 Department of Comparative Biological Sciences, School of Veterinary Medicine, Louisiana State University, Baton Rouge, LA, United States, 8 Department of Biological Sciences and Chemistry, College of Sciences and Engineering, Southern University and A&M College, Baton Rouge, LA, United States, 9 Department of Molecular Medicine, Mayo Clinic, Rochester, MN, United States, 10 Division of Biomedical Sciences, Edward Via College of Osteopathic Medicine, Monroe, LA, United States  \nOncolytic virotherapy (OVT) has emerged as a promising and innovative cancer treatment strategy that harnesses engineered viruses to selectively infect, replicate within, and destroys malignant cells while sparing healthy tissues. Beyond direct oncolysis, oncolytic viruses (OVs) exploit tumor-speciﬁc metabolic, antiviral, and immunological vulnerabilities to reshape the tumor microenvironment (TME) and initiate systemic antitumor immunity. Despite promising results from preclinical and clinical studies, several barriers, including inefﬁcient intratumoral virus delivery, immune clearance, and tumor heterogeneity, continue to limit the therapeutic advantages of OVT as a standalone modality and hindered its clinical success. Recent advances in OV engineering have enhanced viral tropism, immune evasion, and transgene delivery, enabling b","cbCairclvmM1Bxwv","https://ap.wps.com/l/cbCairclvmM1Bxwv","pdf",4547285,34,"English","# Introduction\n## Oncolytic viruses and tumor vulnerabilities\n## History and landmark oncolytic therapies","[{\"question\":\"How do engineered oncolytic viruses treat cancer beyond direct tumor cell killing?\",\"answer\":\"They can remodel the tumor microenvironment by exploiting tumor-specific vulnerabilities and trigger systemic antitumor immunity, including immunogenic cell death and T-cell infiltration and activation.\"},{\"question\":\"What main barriers limit the clinical success of oncolytic virotherapy as a standalone treatment?\",\"answer\":\"Key barriers include inefficient intratumoral virus delivery, immune clearance, and tumor heterogeneity, which reduce therapeutic effectiveness.\"},{\"question\":\"What types of progress are discussed for improving oncolytic virus performance?\",\"answer\":\"The review highlights advances in OV engineering that enhance viral tropism, immune evasion, and transgene delivery, supporting better targeting, penetration, and sustained immune activation.\"}]","Viral warfare - unleashing engineered oncolytic viruses to outsmart cancer’s defenses - Review | PDF",1790146259,86,[148,152,156,160],{"page_no":22,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8b99ddd6524ddf966fef426d4e51cbde.webp",983,1389,{"page_no":26,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/645957a22f520932d7f7973a115a8d01.webp",982,1388,{"page_no":30,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4394b79724735022fc98084c0482f33e.webp",981,1386,{"page_no":33,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b582c4cc741d6b928c8d1fa6a56eaa38.webp",980,1385]